Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Edema 2Brain Neoplasms 2Brain Edema 2Astrocytoma 2

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × Corticotropin-Releasing Hormone × Clear all
NCT00088166 2014-08-13

XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors

Celtic Pharma Development Services

Phase 3 Completed
200 enrolled 17 charts
CNS

Astrocytoma, Brain Edema, Brain Neoplasms, Edema

NCT00226655 2012-08-31

An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies

Celtic Pharma Development Services

Phase 3 Completed
112 enrolled 8 charts
CNS

Astrocytoma, Brain Edema, Brain Neoplasms, Edema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡